109 related articles for article (PubMed ID: 17461712)
1. Severe anaphylactic reaction after repeated intermittent exposure to lepirudin.
Veach SA; Franks AM; Allan MC
Pharmacotherapy; 2007 May; 27(5):760-5. PubMed ID: 17461712
[TBL] [Abstract][Full Text] [Related]
2. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.
Greinacher A; Lubenow N; Eichler P
Circulation; 2003 Oct; 108(17):2062-5. PubMed ID: 14568897
[TBL] [Abstract][Full Text] [Related]
3. Excessive anticoagulation and anaphylactic reaction after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia.
Badger NO; Butler K; Hallman LC
Pharmacotherapy; 2004 Dec; 24(12):1800-3. PubMed ID: 15585446
[TBL] [Abstract][Full Text] [Related]
4. Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia.
Cardenas GA; Deitcher SR
Mayo Clin Proc; 2005 Apr; 80(4):491-3. PubMed ID: 15819285
[TBL] [Abstract][Full Text] [Related]
5. Recommended and actual lepirudin doses in patients with renal insufficiency.
Saxer SB; Smith BS; Gandhi PJ; Tataronis GR; Krikorian SA
Am J Health Syst Pharm; 2003 Dec; 60(24):2588-93. PubMed ID: 14735776
[No Abstract] [Full Text] [Related]
6. Lepirudin in the management of heparin-induced thrombocytopenia.
Gajra A; Husain J; Smith A
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1131-41. PubMed ID: 18680447
[TBL] [Abstract][Full Text] [Related]
7. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients.
Tschudi M; Lämmle B; Alberio L
Blood; 2009 Mar; 113(11):2402-9. PubMed ID: 19059879
[TBL] [Abstract][Full Text] [Related]
8. Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease.
Linnemann B; Greinacher A; Lindhoff-Last E
Vasa; 2010 Feb; 39(1):103-7. PubMed ID: 20186683
[TBL] [Abstract][Full Text] [Related]
9. Lepirudin-induced thrombocytopenia following subcutaneous administration.
Schroeder WS; Tran MT; Gandhi PJ
Am J Health Syst Pharm; 2009 May; 66(9):834-7. PubMed ID: 19386946
[TBL] [Abstract][Full Text] [Related]
10. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.
Lubenow N; Eichler P; Lietz T; Farner B; Greinacher A
Blood; 2004 Nov; 104(10):3072-7. PubMed ID: 15280202
[TBL] [Abstract][Full Text] [Related]
11. [Heparin-induced thrombocytopenia type II. Intra- and postoperative lepirudin treatment in acute ischemia of the extremities].
Schmidt O; Lang W
Dtsch Med Wochenschr; 1998 Oct; 123(41):1207-10. PubMed ID: 9810286
[TBL] [Abstract][Full Text] [Related]
12. Arthus reaction to lepirudin, a new recombinant hirudin, and delayed-type hypersensitivity to several heparins and heparinoids, with tolerance to its intravenous administration.
Jappe U; Reinhold D; Bonnekoh B
Contact Dermatitis; 2002 Jan; 46(1):29-32. PubMed ID: 11918584
[TBL] [Abstract][Full Text] [Related]
13. Dosage of lepirudin in renal failure.
Shepherd MF
Am J Health Syst Pharm; 2002 Jan; 59(1):77-8. PubMed ID: 11813471
[No Abstract] [Full Text] [Related]
14. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Kiser TH; Jung R; MacLaren R; Fish DN
Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
[TBL] [Abstract][Full Text] [Related]
15. Lepirudin is a safe and effective anticoagulant for patients with heparin-associated antiplatelet antibodies.
Mudaliar JH; Liem TK; Nichols WK; Spadone DP; Silver D
J Vasc Surg; 2001 Jul; 34(1):17-20. PubMed ID: 11436069
[TBL] [Abstract][Full Text] [Related]
16. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance.
Greinacher A; Eichler P; Albrecht D; Strobel U; Pötzsch B; Eriksson BI
Blood; 2003 Apr; 101(7):2617-9. PubMed ID: 12393696
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient.
Nowak G; Bucha E; Brauns I; Czerwinski R
Wien Klin Wochenschr; 1997 May; 109(10):354-8. PubMed ID: 9200807
[TBL] [Abstract][Full Text] [Related]
18. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M
Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527
[TBL] [Abstract][Full Text] [Related]
19. Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization.
Iqbal O; Tobu M; Aziz S; Gerdisch M; Da Valle M; Demir M; Hoppensteadt DA; Ahmad S; Walenga JM; Fareed J
J Card Surg; 2005; 20(1):42-51. PubMed ID: 15673409
[TBL] [Abstract][Full Text] [Related]
20. Lepirudin: is the approved dosing schedule too high?
Hacquard M; de Maistre E; Lecompte T
J Thromb Haemost; 2005 Nov; 3(11):2593-6. PubMed ID: 16241965
[No Abstract] [Full Text] [Related]
[Next] [New Search]
